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Abstract: The mARC (mitochondrial Amidoxime Reducing Component) proteins are recently
discovered molybdenum (Mo) Cofactor containing enzymes. They are involved in the reduction
of several N-hydroxylated compounds (NHC) and nitrite. Some NHC are prodrugs containing an
amidoxime structure or mutagens such as 6-hydroxylaminopurine (HAP). We have studied this
protein in the green alga Chlamydomonas reinhardtii (crARC). Interestingly, all the ARC proteins need
the reducing power supplied by other proteins. It is known that crARC requires a cytochrome b5
(crCytb5-1) and a cytochrome b5 reductase (crCytb5-R) that form an electron transport chain from
NADH to the substrates. Here, we have investigated NHC reduction by crARC, the interaction
with its partners and the function of important conserved amino acids. Interactions among crARC,
crCytb5-1 and crCytb5-R have been studied by size-exclusion chromatography. A protein complex
between crARC, crCytb5-1 and crCytb5-R was identified. Twelve conserved crARC amino acids
have been substituted by alanine by in vitro mutagenesis. We have determined that the amino acids
D182, F210 and R276 are essential for NHC reduction activity, R276 is important and F210 is critical
for the Mo Cofactor chelation. Finally, the crARC C-termini were shown to be involved in protein
aggregation or oligomerization.
Keywords: mARC; Chlamydomonas; amidoxime; HAP; molybdenum; partners; interaction;
oligomers
1. Introduction
Mo is the only second-row transition metal that participates in critical biological functions in
most living beings from bacteria to humans [1]. For gaining biological activity and fulfilling its
function in enzymes, all studied eukaryotic Mo enzymes have Mo chelated by a tricyclic pyranopterin
compound called molybdopterin (MPT), thus forming the Mo Cofactor [2] (Figure 1). The Mo
Cofactor is widespread in all kingdoms and synthesized by a very conserved pathway [3]. The
Mo Cofactor takes part in the active centre of more than fifty different enzymes involved in key
reactions of nitrogen and sulphur metabolism, phytohormone biosynthesis and detoxification of
xenobiotics. Most of these Mo-containing enzymes occur in prokaryotes while only five of them have
been identified in eukaryotes: nitrate reductase (NR), sulphite oxidase (SO), aldehyde oxidase (AO),
xanthine oxidoreductase (XOR), and mARC the last one uncovered [4].
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(XO) family of Mo Cofactor enzymes [1]. However except for the MOS, all other members of the 
MOSC superfamily, including mARC, are proteins without any confirmed physiological function. 
 
Figure 1. Scheme of NHC reduction to N-compounds (NC) by the Chlamydomonas ARCO. Each 
protein involved is represented schematically in boxes. The crARC protein is able to bind Mo Cofactor, 
which is indicated by the Mo Cofactor chemical structure above the protein box. In bold, the Mo atom, 
bound to the organic motif MPT, illustrating that the fifth Mo ligand in crARC is the cysteine 252. In 
vitro, the NHC reduction (HAP or benzamidoxime) mediated by crARC to NC (adenine or 
benzamidine, respectively) could occur in two ways, using dithionite or NADH as electron donors. 
Dithionite is an artificial electron donor that directly donates the electrons to the crARC Mo centre 
which is indicated by the arrow. The NADH donates the electrons to crCytb5-R, then to crCytb5-1, 
and then to the crARC Mo centre where NHC reduction takes place. 
Investigation of the aerobic reduction of NHC led to the discovery of an unknown Mo enzyme 
[4]. The protein was named “mitochondrial amidoxime reducing component” (mARC), because 
initially, reduction of amidoxime structures was studied with this enzyme purified from porcine liver 
mitochondria. Afterwards, it was discovered that mARC proteins are also widely distributed and 
involved in reducing a broad range of other NHC [6]. It is well accepted that the human enzyme 
system contributes to reductive xenobiotic metabolism, in particular, activation of N-hydroxylated 
prodrugs [7]. Further substrates are the base analogs HAP [8] and the N-hydroxy-cytosine [9,10], 
which are very powerful mutagens in phage, bacteria and eukaryotic cells [11]. In bacteria, the defect 
in any enzyme involved in the Mo Cofactor biosynthesis pathway gives a HAP-hypersensitive 
phenotype, the first evidence seen in an Mo Cofactor dependent enzyme involved in the 
detoxification of HAP [12]. 
Interestingly, the mARC enzymes need additional proteins which act as their partners and 
donate the reducing power necessary for the substrate reductions. Therefore, we proposed that the 
complex formed between mARC and their partners can be called ARCO (Amidoxime Reducing 
COmplex) [13]. Humans, similar to many eukaryotes, contain two mARC versions (hmARC1 and 
hmARC2), which both show strong similarities at amino acid and nucleotide levels. In the presence 
of NADH, each human Mo enzyme exerts reductase activity towards NHCs with cytochrome b5 [14] 
and NADH cytochrome b5 reductase [15]. However, the bacterial ARCO is a two-component system 
that uses ferredoxin fused to the C-termini mARC enzyme (YcbX) instead of cytochrome and as a 
second component, uses flavin reductase (CysJ) instead of NADH cytochrome b5 reductase [16]. 
The first ARCO studied in detail in the plant kingdom was in the alga (Chlamydomonas reinhardtii) 
(Chlamydomonas). We found that Chlamydomonas ARCO is the Mo enzyme crARC, the cytochrome 
b5-1 (crCytb5-1) and one NADH cytochrome b5 reductase (crCytb5-R) (Figure 1), similar to its human 
counterpart and different from the two components in a prokaryotic system [17]. The 
Chlamydomonas ARCO is able to reduce HAP to adenine, shows a Zn2+-dependent activity that 
increases its Vmax more than 14-fold, and belongs to the SO family since its Cysteine 252 was identified 
as a putative ligand of the Mo atom [17] (Figure 1). 
At present, the physiological role of ARCO is a matter of intense debate [7]. In addition to NHC, 
mARC is able to reduce other kinds of substrates, like nitrite [18]; however, using different kinds of 
Figure 1. Scheme of NHC reduction to N-compounds (NC) by the Chlamydomonas ARCO. Each
protein involved is represented sche atically in boxes. The crARC protein is able to bind Mo Cofactor,
which is indicated by the Mo Cofactor chemical structure above the protein box. In bold, the Mo
atom, bound to the organic motif MPT, illustrating that the fifth Mo ligand in crARC is the cysteine
252. In vitro, the NHC reduction (HAP or benzamidoxi e) mediated by crARC to NC (adenine or
benzamidine, respectively) could occur in two ways, using dithionite or NADH as electron donors.
Dithionite is an artificial electron donor that directly donates the electrons to the crARC Mo centre
which is indicated by the arrow. The NADH donates the electrons to crCytb5-R, then to crCytb5-1, and
then to the crARC Mo centre where NHC reduction takes place.
mARC pr teins are members of the MOSC protein superfamily [5]. These proteins contain a
domain h mologous to the C-terminal domain (MOSC) that is also present in the eukaryotic Mo
Cofacto S lphurases (MOS). The MOS enzymes are involved in the transf r of a sulfide ligand
y elding a sulfurated ver ion of the Mo Cofactor which is essential fo the activ ty of xanthine oxidase
(XO) fam ly of Mo Cofactor enzymes [1]. However except for th MOS, all other members of the MOSC
superfamily, including mARC, ar proteins wi hout any confi med physiological function.
Investigation of the aerobic reduction of NHC led to the discovery of an unknown M e zyme [4].
T e protein was named “mitochondrial midoxime reducing component” (mARC), bec use initially,
reduction of amid xime structures was studied with this enzyme purified from o cine li r
mitochondria. Afterwar s, it was discovered that mARC protei s are also widely distributed and
involved in reducing a broad range of other NHC [6]. It is well accepted that the human enzyme
system contributes to reductive xenobiotic metabolism, in particular, activation of N-hydroxyl ted
prodrugs [7]. Further substrates are the base analogs HAP [8] and the N-hydroxy-cytosine [9,10], which
are very pow rful mutagens in ph ge, bacteria and euk ryotic cells [11]. In bacteria, the defect in any
enzym involved in the Mo Cof ctor bios nthesis pathway gives a HAP-hypersensitive phenotype, the
first evidence seen in an Mo Cofactor dependent enzyme involved in the detoxification of HAP [12].
Interestingly, the mARC enzymes need addition l proteins which act as their partners and donate
the reducing p wer necessary for the substrate reductions. Therefore, we prop sed that the complex
formed betw en mARC and their partners can be called ARCO (Amidoxime Reducing COmplex) [13].
Humans, similar to many eukaryotes, contain two mARC versions (hmARC1 and hmARC2), which
both show strong similarities at mi o acid and ucleotide levels. In the presence f NADH, each
human Mo e zyme xerts reductase activity towards NHCs with cytochrome b5 [14] and NADH
cytochrome b5 re uctase [15]. However, the bacteri l AR O is a two-component system t at uses
ferredoxin fused to the C-termini mARC enzy e (YcbX) instead of cytochrome and as a second
component, uses flavin reductase (CysJ) instead of NADH cytochrome b5 re uctase [16].
The first ARCO studied in detail in the plant kingdom was in th alga (Chlamydomonas rei hardtii)
(Chlamydomonas). We found that Chlamydomonas ARCO is the Mo enzyme crARC, the cytochrome
b5-1 (crCytb5-1) and one NADH cytochrome b5 reductas (crCytb5-R) (Figure 1), similar to its human
counterp rt and differ nt from the two compon nts in a prokaryotic system [17]. The Chlamydomonas
ARCO is able to reduce HAP to adenine, shows a Zn2+-dependent activity that increases its Vmax more
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than 14-fold, and belongs to the SO family since its Cysteine 252 was identified as a putative ligand of
the Mo atom [17] (Figure 1).
At present, the physiological role of ARCO is a matter of intense debate [7]. In addition to
NHC, mARC is able to reduce other kinds of substrates, like nitrite [18]; however, using different
kinds of partners for each of them, like NR [19]. Recently, apart from NHC reduction, the mARC
proteins have been shwon to be involved in NO synthesis by different ways. In this regard, in vitro
studies have shown that human ARCO is also able to catalyze the reduction of the NO precursor
N-omega-hydroxy-L-arginine (NOHA) to arginine [20]. In this sense, a variety of several enzymes have
been involved with in vitro synthesis of NO by reducing nitrite, and Mo enzymes like NR, SO and
XOR appear in many of them [21]. The human ARCO apart from the NHC and NOHA reductions is
also able to catalyze the reduction of nitrite to NO using cytochrome b5-1 and cytochrome b5 reductase
as partners [18], however, only under anaerobic conditions.
Interestingly, in the process of NO synthesis in Chlamydomonas, the NR, another Mo enzyme, is
able to replace very efficiently in ARCO the function of crCytb5-R and crCytb5-1 and reduce nitrite
to NO [19]. Therefore, this new mARC activity able to synthesize NO but NR-dependent has been
renamed as NOFNiR (Nitric Oxide Forming Nitrite Reductase) [19]. Here, we have not addressed the
NOFNiR dual system crARC-NR involved in the NO synthesis; rather, we have focused on the NHC
reduction catalyzed by crARC, crCytb5-1 and crCytb5-R. Also, we have described the crARC stability at
different temperatures, the stoichiometry of the interaction between crARC and its partners crCytb5-1
and crCytb5-R, and the function of different crARC conserved amino acids in NHC reduction activity.
2. Results
2.1. The Temporal Stability of the crARC Activity
There is still no report of the behavior of any mARC proteins over the time of the reduction
activity. It is known that the activity under aerobic conditions of most Mo Cofactor proteins is very low,
and usually after a few hours they start to lose their activity [22]. Accordingly, we have studied the
stability of crARC activity at 22 and 4 ◦C by determining its NHC reduction activity at different times.
The NHC substrate selected to be reduced in this assay was the model substrate
benzamidoxime [4]. The crARC reduction activity was determined in vitro in two ways, using either
dithionite or NADH as electron donors. Dithionite is an artificial electron donor, which in vitro directly
donates the electrons to the crARC Mo centre without the need of its protein partners (Figure 1).
Nevertheless, the NADH donates the electrons to crCytb5-R, which afterward go to crCytb5-1 and
then to the crARC Mo centre where the NHC reduction takes place, as shown in Figure 1. The use of
two different electron donors allows a better understanding of the reason why crARC loses its activity.
If crARC loses its dithionite-dependent activity, it will be considered that its Mo Cofactor centre is not
working properly. However, if crARC only loses its NADH dependent activity, it is because crARC
does not have a proper interaction with its partners, crCytb5-1 and crCytb5-R.
As shown in Figure 2a after incubation at 22 ◦C, crARC showed higher activity with dithionite
than with NADH. The crARC activity measured with NADH after 72 h of incubation at 22 ◦C was only
around 20% of the initial activity. However, under the same condition, this activity with dithionite was
still 80% of the initial value. This means that the crARC stability at 22 ◦C was very high, since in both
cases, its activity took several hours, around 100, to disappear completely.
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Figure 2. The crARC thermal and temporal stability. The crARC protein was incubated at (a) 22 °C or 
at (b) 4 °C for the indicated times and then the crARC activity was assayed in vitro using 
benzamidoxime as a substrate and either dithionite or NADH plus crCytb5-1 and crCytb5-R as 
electrons donors. The detection limit was 0.06 mU/nmol. 
2.2. The Interaction of crARC, crCytb5-1 and crCytb5-R 
As shown previously, in vivo crARC needs two other proteins, crCytb5-1 and crCytb5-R, to carry 
out NHC reduction from NADH [17]. The highest reductase activity was obtained with an enzyme 
system reconstituted in vitro at a ratio of approximately 1:1:0.1 (crARC:crCytb5-1:crCytb5-R) with 
the human and Chlamydomonas system [15,17]. We performed a series of experiments to verify if 
there is indeed a real protein complex between these three proteins, to know its stoichiometry and 
whether or not it coincides with the obtained for the enzyme system reconstituted. We studied the 
interactions of these three proteins by size exclusion chromatography (SEC). SEC is a simple and mild 
chromatographic technique that separates molecules on the basis of size differences. In addition, a 
strong enough interaction among the proteins studied is needed to be maintained during the course 
of the SEC, which would result in changes of the chromatographic profiles of the protein mix with 
respect to those of separate proteins. The high crARC temporal stability found previously allowed us 
to perform the SEC with the confidence of no protein degradation until the end of experiment. 
The proteins crARC, crCytb5-1 and crCytb5-R were incubated either alone or together for 10 
minutes and then the samples were loaded on a SEC column. If during the incubation period, any 
kind of protein complex is formed, the elution profile will change with respect to those of proteins 
loaded alone. The molecular weight (MW) of eluted proteins or complex will be estimated by 
comparing with protein markers of known MW loaded under the same conditions (Figure 3e). 
It is important to note that for some proteins, the MW estimated by SEC are larger than those 
predicted from their amino acids sequence. This means that the MW obtained by SEC can be 
overestimated. This overestimation happens because the proteins have to pass through the pores of 
the column in a spherical way and the remaining volume to complete the spherical shape is added 
[24]. That is not the case of the proteins markers used, which are close to spheres. However, 
underestimation of molecular weight by SEC is conceivable as well [25]. 
Figure 3a shows the SEC profiles of the proteins crARC, crCytb5-R and crCytb5-1 when they 
were loaded alone. The estimated Mw of the main peak obtained with crARC was 35 kDa (Figure 3a, 
in blue), which is very close to 35.1 kDa, the predicted Mw of one crARC monomer. This indicates 
that in the absence of its partners, crARC occurs mostly as a monomer, as reported for the N-terminal 
truncated homologue hmARC1 [26]. The estimated Mw of the crCytb5-1 peak was 24 kDa (Figure 3a, 
in red). The predicted Mw of one crCytb5-1 was 12.7 kDa, which indicates that crCytb5-1 occurs as a 
dimer in the absence of its partner. 
The estimated Mw for crCytb5-R alone was 30 kDa (Figure 3a, in green), which is close to its 
predicted value, 28.7 kDa, suggesting that this protein occurs as a monomer in the absence of partners. 
The crARC and crCytb5-1 incubated together showed a main peak with an estimated Mw of 64 kDa 
Figure 2. The crARC thermal and temporal stability. The crARC protein was incubated at (a) 22 ◦C or at
(b) 4 ◦C for the indicated times and then the crARC activity was assayed in vitro using benzamidoxime
as a substrate and either dithionite or NADH plus crCytb5-1 and crCytb5-R as electrons donors. The
detection limit was 0.06 mU/nmol.
As shown in Figure 2b, when crARC was incubated at 4 ◦C, its activity with dithionite was always
from 2 to 5 times higher than with NADH. At 4 ◦C, the NADH-dependent crARC activity disappeared
after 23 days; however, with dithionite, 80% of its initial activity was still observed. The crARC activity
with dithionite took around 28 days to disappear. From these data, it can be concluded that the crARC
protein protects the Mo Cofactor bound to its active centre very efficiently. Generally, the half-lives of
the activity of the main known Mo enzymes are very short at room temperatures [23]. Therefore, in
comparison to the other Mo enzymes, crARC seems to be different in this aspect.
2.2. The Interaction of crARC, crCytb5-1 and crCytb5-R
As shown previously, in vivo crARC needs two other proteins, crCytb5-1 and crCytb5-R, to carry
out NHC reduction from NADH [17]. The highest reductase activity was obtained with an enzyme
system reconstituted in vitro at a ratio of approximately 1:1:0.1 (crARC:crCytb5-1:crCytb5-R) with
the human and Chlamydomonas system [15,17]. We performed a series of experiments to verify if
there is indeed a real protein complex between these three proteins, to know its stoichiometry and
whether or not it coincides with the obtained for the enzyme system reconstituted. We studied the
interactions of these three proteins by size exclusion chromatography (SEC). SEC is a simple and mild
chromatographic technique that separates molecules on the basis of size differences. In addition, a
strong enough interaction among the proteins studied is needed to be maintained during the course
of the SEC, which would result in changes of the chromatographic profiles of the protein mix with
respect to those of separate proteins. The high crARC temporal stability found previously allowed us
to perform the SEC with the confidence of no protein degradation until the end of experiment.
The proteins crARC, crCytb5-1 and crCytb5-R were incubated either alone or together for 10 min
and then the samples were loaded on a SEC column. If during the incubation period, any kind of
protein complex is formed, the elution profile will change with respect to those of proteins loaded
alone. The molecular weight (MW) of eluted proteins or complex will be estimated by comparing with
protein markers of known MW loaded under the same conditions (Figure 3e).
It is important to note that for some proteins, the MW estimated by SEC are larger than those
predicted from their amino acids sequence. This means that the MW obtained by SEC can be
overestimated. This overestimation happens because the proteins have to pass through the pores of
the column in a spherical way and the remaining volume to complete the spherical shape is added [24].
That is not the case of the proteins markers used, which are close to spheres. However, underestimation
of molecular weight by SEC is conceivable as well [25].
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(Figure 3b, in blue), which is compatible with the complex of 1 crARC and 2 crCytb5-1 (predicted Mw 
of 60.5 kDa). The other peak that appears has an estimated Mw of 24 kDa and probably corresponds 
to an excess of crCytb5-1 dimers (Figure 3b). 
 
Figure 3. Interaction studies between crARC, crCytb5-1 and crCytb5-R. The SEC profiles of the 
indicated samples are shown. In these experiments, the proteins crARC, crCytb5-1 and crCytb5-R 
were loaded separately and then together in different combinations to observe the appearance of new 
peaks. (a) The proteins loaded separately; (b) crARC, with crCytb5-1, and crARC with crCytb5-R; (c) 
The crCytb5-1 protein with crCytb5-R; (d) The proteins crARC plus, crCytb5-1 and crCytb5-R 
together; (e) Calibration curve obtained using the Mw protein marker; the graph represents the Mw 
versus the logarithm of the elution volume. The absorbance was measured at 280 nm; (f) sodium 
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis of the protein peak indicated with the 
symbol * obtained in the SEC. 
  
Figure 3. Interaction studies between crARC, crCytb5-1 and crCytb5-R. The SEC profiles of the
indicated samples are shown. In these experiments, the proteins crARC, crCytb5-1 and crCytb5-R were
loaded separately and then together in different combinations to observe the appearance of new peaks.
(a) The proteins loaded separately; (b) crARC, with crCytb5-1, and crARC with crCytb5-R; (c) The
crCytb5-1 protein with crCytb5-R; (d) The proteins crARC plus, crCytb5-1 and crCytb5-R together;
(e) Calibration curve obtained using the Mw protein marker; the graph represents the Mw versus the
logarithm of the elution volume. The absorbance was measured at 280 nm; (f) sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis of the protein peak indicated with the symbol * obtained in
the SEC.
Figure 3a shows the SEC profiles of the proteins crARC, crCytb5-R and crCytb5-1 when they were
loaded alone. The estimated Mw of the main peak obtained with crARC was 35 kDa (Figure 3a, in
blue), which is very close to 35.1 kDa, the predicted Mw of one crARC monomer. This indicates that
in the absence of its partners, crARC occurs mostly as a monomer, as reported for the N-terminal
truncated homologue hmARC1 [26]. The estimated Mw of the crCytb5-1 peak was 24 kDa (Figure 3a,
in red). The predicted Mw of one crCytb5-1 was 12.7 kDa, which indicates that crCytb5-1 occurs as a
dimer in the absence of its partner.
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The estimated Mw for crCytb5-R alone was 30 kDa (Figure 3a, in green), which is close to its
predicted value, 28.7 kDa, suggesting that this protein occurs as a monomer in the absence of partners.
The crARC and crCytb5-1 incubated together showed a main peak with an estimated Mw of 64 kDa
(Figure 3b, in blue), which is compatible with the complex of 1 crARC and 2 crCytb5-1 (predicted Mw
of 60.5 kDa). The other peak that appears has an estimated Mw of 24 kDa and probably corresponds to
an excess of crCytb5-1 dimers (Figure 3b).
The SEC of crARC and crCytb5-R incubated together gave a peak with an estimated Mw of
72 kDa (Figure 3b, in purple), compatible with a complex of 1 crARC and 1 crCytb5-R (predicted
Mw of 63.8 kDa). Also, a minor peak of 30 kDa appeared that probably corresponds to an excess of
crCytb5-R monomers (Figure 3a). When crCytb5-R and crCytb5-1 were incubated together after the
SEC, two peaks were observed with an estimated Mw of 81 kDa for the wider and 30 kDa for the
thinner one (Figure 3c). The wider peak corresponds to a complex of 1 crCytb5-R and 4 crCytb5-1
(predicted Mw of 79.8 kDa), and the thinner one corresponds to an excess of crCytb5-R monomers.
When the three proteins (crARC + crCytb5-1 + crCytb5-R) were incubated together, after the
SEC, the chromatogram showed a main peak with an estimated Mw of 105 kDa and one smaller
one with Mw of 35 kDa (Figure 3d). The minor peak of 35 kDa would correspond to an excess of
crARC monomers. It is remarkable that this 105 kDa peak only appeared when the three proteins were
incubated together. Therefore, it was probably formed due to some kind of interaction among the three
proteins. The 105 kDa complex is compatible with a composition of 1:2:1 (predicted Mw of 89.2 kDa),
1:3:1 (predicted Mw of 101.9 kDa) or 1:1:2 (predicted Mw of 105.2 kDa) for crARC-crCytb5-1-crCytb5-R.
Other possible stoichiometries like 1:2:2, or 2:1:1 have been rejected because their predicted Mw are
considerably higher than 105 kDa.
To determine whether the SEC peaks were formed by the proposed protein complexes, the
fractions of the main peaks in each chromatographic profiles were loaded on a polyacrylamide gel
for electrophoresis. The analyzed peaks are those marked with an asterisk in Figure 3. As shown in
Figure 3f, all the protein bands that appeared in the gel are in agreement with the proposed interactions.
As can be seen in the gel electrophoresis, the 105 kDa peak is related to the complex of the three proteins,
crARC + crCytb5-1 + crCytb5-R (Figure 3f).
To study if this three-protein complex is catalytically active after SEC, we measured its
benzamidoxime reduction activity with just NADH and without adding any additional proteins
partners. An activity of 0.547 ± 0.082 mU/nmol protein was obtained. The benzamidoxime reduction
of the mixture before its loading to the SEC column was 0.861 ± 0.129 mU/nmol protein. This means
that this complex retained 63% of its activity after SEC. Therefore, in this complex, the three proteins
are assembling properly to perform the catalysis and retain its enzymatic activity.
2.3. Study of Different crARC Variants
Several crARC point mutant variants in different conserved amino acids were constructed and
their behaviors were compared with the wild type protein afterwards. Figure 4 shows the alignment
of crARC with other mARC from organisms of different kingdoms where different conserved amino
acids are highlighted. We have generated 12 different variants exchanging the indicated amino acids
for alanine. Once obtained, the recombinant proteins were over expressed and purified in E. coli
(Escherichia coli). The mutant P268A was discarded because of the low yield obtained in its purification,
probably because the protein appeared in bacterial inclusion bodies. The remaining 11 crARC variants
were purified to proceed further with their characterization and analysis.
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Figure 4. Multiple-sequence alignment of different mARC proteins. The sequences and accession 
numbers (shown into parentheses; GenPept accession numbers begin with XP and NP; others are 
proteins deduced from GenBank sequences) are as follows: crARC, Chlamydomonas reinhardtii mARC 
(XP_001694549); atARC1, Arabidopsis thaliana mARC1 (NP_174376); atARC2, Arabidopsis thaliana 
mARC2 (NP_199285); gvARC Gloeobacter violaceus PCC 7421 mARC (NP_926027); hmARC1, human 
mARC1 (Homo sapiens) (NP_073583); hmARC2, human mARC2 (NP_060368); YcbX, Escherichia coli 
YcbX (NP_415467); ccARC, Caulobacter crescentus mARC (AAK22857); and scARC, Streptomyces 
coelicolor A3ARC (CAC04053). The positions of residues mutated to alanine in crARC are indicated 
by the black arrowheads. Highly conserved amino acids are shown on a black background, and 
moderately conserved amino acids are shown on a gray background. The consensus sequences have 
been calculated with a threshold of 75% with the BioEdit v.7.0.9 program (Reprinted with permission 
from [17]). 
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Figure 4. Multiple-sequence alignment of different mARC proteins. The sequences and accession
numbers (shown into parentheses; GenPept accession numbers begin with XP and NP; others are
proteins deduced from GenBank sequences) are as follows: crARC, Chlamydomonas reinhardtii mARC
(XP_001694549); atARC1, Arabidopsis thaliana mARC1 (NP_174376); atARC2, Arabidopsis thaliana
mARC2 (NP_199285); gvARC Gloeobacter violaceus PCC 7421 mARC (NP_926027); hmARC1, human
mARC1 (Homo sapiens) (NP_073583); hmARC2, human mARC2 (NP_060368); YcbX, Escherichia coli YcbX
(NP_415467); ccARC, Caulobacter crescentus mARC (AAK22857); and scARC, Streptomyces coelicolor
A3ARC (CAC04053). The positions of residues mutated to alanine in crARC are indicated by the
black arrowheads. Highly conserved amino acids are shown on a black background, and moderately
conserved amino acids are shown on a gray background. The consensus sequences have been calculated
with a threshold of 75% with the BioEdit v.7.0.9 program (Reprinted with permission from [17]).
The substituted amino acid should not perturb the overall folding of the crARC protein, and if it
happens, the mutant should be iscarded. Therefo e, o find out whether the overall tree dimensional
(3D) crARC s ructure of hese 11 mutant ha changed compared with the ild type, the fluo escenc
spectrum of aromatic amino a ids of those proteins wa compared to that of th wild typ . As crARC
has 10 tryptophans distributed along its sequence, if any of the ubstitutions affect the folding of
he protein, its fluorescence s ectrum will be altered. Therefore, the maximum of fluorescence and
spectrum shape of he crARC variants have to be the sam s th wild type crARC; otherwise, it
indicates that the overall 3D structur variants has been ff cted by changing the amino acid.
After the analysis the 8 crARC v riants G17A, L139A, D182A, F210A, R211A, E224A, E267A and
R276A had fluorescen e spec ra very similar to the wild type pro ein cr RC (Figure 5). However,
3 variants, N213A, D225A, and L272A had notable differences compared with the il , c ARC.
In these 3 variants, the maximum peak appeared at different wavelength compared with the wil
type, 328 nm instead of 332 nm, and showed houlders n their spectrum different from he wild type
(Figure 5). This indicates hat the overall 3D structures of these 3 variant are ifferen from the wild
typ crARC protein, probably because t e changed amino acids were involved in maintaining the
overall 3D crARC s ructure. Therefore, these 3 variants were r jected for further analysis.
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2.4. The Reduction Activity of the crARC Variants
Thus far, the crystallographic 3D structure of mARC has not been resolved. Therefore, we
observed in silico predicted structure of crARC (Figure 6) to locate the positions of the 8 amino acids,
G17, L139, D182, F210, R211, E224, E267 and R276. In this predicted structure, we have also located the
two amino acids, C252 and C249, which previously showed involvement in the Mo Cofactor binding
to crARC [17].
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Figure 6. Predicted in silico crARC protein structure. The structures were obtained with
Swiss-PdbViewer and Swiss-model programs in (a) secondary structure and in (b) protein surface. This
structure was made in two parts, because the part with the β-barrel domain presents an identity of
32.2% with the BoR11 protein (2exn.1.A); on the other hand, the second part (MOSC domain) presents
an identity of 14.88% with the yuaD protein (1oru.1.A). The N-terminus is in green, and the C terminus
in blue, the Mo Cofactor is in red, in black is the Mo, in yellow are the cysteines 249 and 252 connecting
the Mo Cofactor and in purple are the mutated residues.
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A good indication of the role of each studied amino acid in the crARC function is to know their
effect on the reduction activity compared with the wild type. As shown in Figure 2, the crARC activity
was determined in two ways, either using dithionite or using crCytb5-1 and crCytb5-R with NADH as
electron donors. The results of these experiments (Figure 7) showed that the mutants, D182A, F210A
and R276A almost completely lost the mARC activity with dithionite. Since dithionite donates the
electrons directly to the crARC Mo Cofactor centre (see Figure 1), these residues might play a role in
the suitable Mo Cofactor binding to crARC. As shown in Figure 6, the amino acids D182 and the F210
are in close proximity to the Mo Cofactor centre, which agrees with our hypothesis. However, the
amino acid R276 is not in close proximity to the Mo Cofactor, and it seems not to be directly involved in
the Mo Cofactor chelation. Therefore, R276 could be more strongly involved in a proper Mo Cofactor
binding pocket formation. The crARC activities tested with dithionite of the remaining mutants, G17A,
L139A, R211A, E224A and E267A were very similar to the wild type, which would indicate that these
amino acids are not necessarily related to the Mo Cofactor chelation or the binding pocket formation.
On the other hand, we also measured the crARC activity with NADH, which as mentioned before
needs crCytb5-1 plus crCytb5-R. Consistently, the variants, D182, F210 and R276, which did not have
dithionite dependent activity, do not have NADH dependent activity as well, thus reinforcing the
proposal that in these variants, the Mo Cofactor centre does not work properly.
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The detection limit was 0.045 mU/nmol.
In the 5 other variants, G17A, L139A, R211A, E224A and E267A, the NADH crARC activity tested
was considerably lower than in the wild type except for G17A, which was very similar to the wild type.
The variant E267A was the one with lowest NADH-dependent activity, i.e., only about 25% of the
wild type activity. The NADH crARC reduction activity of the variants L139A, R211A and E224A was
between 50%–60% of the wild type. These data indicate that the amino acids, E267, L139, R211 and
E224 are important but not essential for the correct electron transfer from the NADH to the crARC Mo
Cofactor centre. These data suggest that these 4 amino acids are involved in the interaction between
crARC and its partners, crCytb5-1 and crCytb5-R.
2.5. The o ofactor ontent of the cr ariants
The a ount of o ofactor in the cr variants as easured by high perfor ance liquid
chro atography ( PL ) using the For ethod. s sho n in Figure 8, the utants, 17 , L139 ,
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D182A, R211A, E224A, and E267A showed very similar Mo Cofactor content as the wild type. It is
very interesting that the variant D182A lost its reduction capacity with both dithionite and NADH
(Figure 7); however, it contains the Mo Cofactor, which suggests two possibilities: (i) the Mo Cofactor
bound to the variant D182A could not be in the proper form to accept the electrons form dithionite or
from NADH; and (ii) the Mo Cofactor bound to the D182 variant could accept the electrons but was
not able to donate them to the substrate, perhaps because the substrate could not bind properly. The
variant R276A also lost its reduction capacity with dithionite and NADH (Figure 7), but still retained
30% of the Mo Cofactor content (Figure 8). This indicates that as well as in the variant D182A, the Mo
Cofactor bound is not in the proper form to accept the electrons or to donate them to the substrate.
Interestingly, the variant F210A was the only one studied with no Mo Cofactor bound at all. This
indicates that the F210 is essential for Mo Cofactor binding, which explains the reason of not having
crARC reduction activity. In summary, D182, F210 and R276 are necessary for mARC enzymatic
activity; and for the Mo Cofactor chelation, R276 is important while F210 is essential.
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. cofactor content in the crARC wild type and variants. The content was measured by
the Form A method in a HPLC with a fluoresc n d tector.
2.6. The ligo erization of the crARC Variants
The chro atographic behavior in a SEC colu n of the cr RC variants as also studied.
Interestingly an oligo eric state has been observed in the hu an ho olog h RC1 [27]. Therefore,
the oligo erization degree as studied to distinguish hether they ere all ono ers, just like the
ild type (Figure 3a), or they ight be so e oligo ers. Therefore, the ild type and the different
cr RC variants ere loaded in a SEC colu n, and their chro atographic profiles ere co pared.
As sho n in Figure 3a the wild type crARC protein mostly behaves as a monomer with almost no peak
eluting at around 8 mL. Interestingly, in some of the variants, a huge peak appeared at the volume
of 8 L. This peak can be observed in Figure 9a that shows the chromatographic profile of the wild
type versus the variant R276A. The volume at which this peak appeared indicates an Mw of 1100 kDa,
which corresponds to about 30 crARC units. Figure 9b represents the amount of oligomeric forms that
appears in each of the mutants studied. The variants G17A and W128A look very similar to the wild
protein without almost any oligomeric form. The variants with a higher percentage of the oligomeric
state were E267A and R276A with around 40–50 times more aggregated than the wild type protein.
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The variant R276A has no crARC reduction activity (Figure 7); however, the dithionite-dependent
crARC reduction activity of the E267A was similar to the wild type. Also, mutants with similar
reduction activity like G17A and E224A are monomers and oligomers respectively. These data indicate
that the oligomerization state is not related to the crARC reduction activity.
The variants E224A, R211A and L139A have around 20–30 times higher oligomeric states than
the wild type protein. Figure 7 shows that the crARC reduction activities of these mutants are very
similar to the wild type, which supports the previous hypothesis that the oligomerization state has no
influence on the crARC reduction activity.
The variant F210A shows around 10 times more oligomeric forms than the wild type and has no
Mo Cofactor bound at all. Variants with approximately the same amount of Mo Cofactor have very
differen amo nts of crARC oligomers compared with G17A and E267. These data i dicate that the
amount Mo Cofactor is not th reason why some crARC variants aggregate in oligomers.
3. Discussion
In this study, we have addressed several important points that have not yet been studied in any
protein of the mARC family. Free Mo Cofactor is a very unstable molecule that loses Mo above pH 7.6
under aerobic conditions [28] and has a half-life of around 1 h depending on the components in the
buffer solution [29]. Therefore, under aerobic conditions the Mo Cofactor in Chlamydomonas binds
to a carrier protein (MCP) that is involved in the transfer, storage, protection and insertion of the Mo
Cofactor in the apo-enzyme [22]. Under aerobic conditions, the half-life of the Mo Cofactor bound to
the MCP at 4 ◦C is around 3 days [23], and as shown in Figure 2b at 4 ◦C, the crARC activity has a
half-life of around 20 days and 15 days with dithionite and NADH, respectively. At 22 ◦C, the half-life
of the Mo Cofactor bound to the MCP is around 24 h [23], and 70 h and 55 h for dithionite and NADH
dependent crARC activity, respectively. Thus, crARC is able to protect its bound Mo Cofactor for at
least as long as the MCP at 22 ◦C and even more at 4 ◦C. Therefore, under aerobic conditions, crARC is
a very stable Mo enzyme compared with other Mo enzymes like NR [30]. Human mARC, in addition
to its reduction capacity, has been shown to donate Mo Cofactor to Mo-deficient NR [9]. This fact,
together with the high stability observed in crARC, suggests that crARC might also play a role, under
some conditions, in Mo Cofactor storage or as an insertional protein, buffering the amount of Mo
Cofactor inside the cells. However, this hypothesis needs more future research.
The stoichiometry of the interaction between crARC, crCytb5-1 and crCytb5-R could be 1:2:1, 1:3:1
or 1:1:2 respectively, (Figure 3d); future experiments will be needed to clarify in more detail which
of them is correct. None of these stoichiometries agrees with 1:1:0.1, which has been described in
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Chlamydomonas and humans as the one that produce the highest reductase activity with the enzyme
system reconstituted in vitro [15,17]. It has to be pointed out, that the 1:1:0.1 estimation reflects optimal
conditions of the in vitro reductase assay, while here we have measured and detected the formation
of a protein complex. It has to be noted that the 105 kDa complex is catalytically active and able
to perform the NHC reduction just by adding NADH to the complex, suggesting that this in vitro
complex is not an artifact. We do not yet know the reason for the different stoichiometry between the
protein complex and the reduction system reconstituted in vitro. Therefore, we propose that different
stoichiometric behaviors depending of the organism or the in vivo physiological state may be possible.
The subcellular localization of mARC proteins is not well defined. The mammalian Mo enzyme
is located on the outer mitochondrial membrane. [4,27,31]. Moreover, a location on the inner
mitochondrial membrane [32] as well as peroxisomal location [33] of the Mo is reported as well.
However, NHC reductase activity in humans is strictly dependent on cytochrome b5 reductase
CYB5R3 and mitochondrial cytochrome b5 CYTB5 [14,15]. The latter enzyme seems to be located
solely on the outer membrane [34]. Thus, mammalian ARCO reductase activity is likely exclusively
associated with this submitochondrial compartiment. However, the Arabidopsis and Chlamydomonas
counterparts lack a clear targeting signal for organelle export [3]. This suggests that they could
be free in the cytoplasm. The stoichiometries found among crARC and its partners were obtained
in vitro using purified proteins, but the fact that some mARC proteins are attached to different
subcellular membranes, could change the real in vivo stoichiometry. However, we think that the
in vitro stoichiometries found for the studied proteins are a good first indication of what may be
happening in vivo, though future experiments on this aspect are needed.
From the study of 12 different crARC mutant variants, it was deduced that three amino acids
from crARC, D182, F210 and R276 are essential for NHC reduction (Figure 7), since their mutation
to alanine completely abolished the crARC reduction activity. These mutants might have a deficient
or an incorrect Mo Cofactor binding. We have also identified 4 amino acids E267, L139, R211 and
E224, which are important but not essential for the correct electron flow from NADH to crARC. The
reason may be that these amino acids are involved in the interaction with crCytb5-R or crCytb5-1.
However with the current data, we cannot discriminate which ones of these alternatives would be the
correct one. Interestingly, crARC seems to have basic amino acids in the entire outer part where the Mo
Cofactor is bound, and it has been described that there are mostly acid amino acids in the outside of
crCitb5-1 and crCitb5-R [35], so this would explain in part the interaction between these three proteins.
We have also identified that two amino acids, F210 and R276 (Figure 8), are important for Mo
Cofactor binding. The variant R276A had around 30% of the wild type Mo Cofactor content, which
suggests that this residue is notably important but not essential for Mo Cofactor binding. However,
amino acid R276 is not in close proximity to the Mo Cofactor, similar to F210. Therefore, R276 could
not be directly involved in Mo Cofactor chelation; instead, it could be involved in a proper Mo cofactor
binding pocket formation. Therefore, we propose that R276 might be involved in proper Mo Cofactor
accommodation in the crARC active centre. Notwithstanding, F210 is essential since its exchange
completely abolished the Mo Cofactor binding. In previous experiments, we detected that C252 is also
essential for Mo Cofactor binding [17]. The predicted in silico crARC structure (Figure 6) shows that
F210 is in close proximity to where the Mo Cofactor is supposed to bind. This work has highlighted
F210, as previously found for C252, to be a critical residue for Mo Cofactor binding.
The mARC proteins contain two conserved domains: an N-terminal β-barrel domain and a
C-terminal MOSC domain [5]. The mARC proteins show several conserved patches of hydrophobic
residues and the absolutely conserved cysteine located in the C-terminus, which could be considered
part of their signature [17]. The N-terminal β-barrel domain, which in standalone form is undetectable
in other proteins, is predicted to build a β sheet-rich fold like structure. This particular domain may
have specific roles in interaction with substrates of these enzymes. In the predicted mARC structure
(Figure 6), it can be observed that from A66 to P79, there is a β sheet with the hydrophobic charge
exposed to the outside, which possibly can be used to interact with a membrane as suggested in
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the human mARC [27]. The mARC β sheet has also been involved in the origin of the aggregates
formation occurring in the human mARC [27]. However, we have not mutated the amino acids of this
domain in crARC so it is unknown whether this β sheet is also involved in the aggregate formation
in Chlamydomonas. The mammalian SO is another Mo enzyme where a high degree of oligomeric
forms has been detected [36] probably due to the lack of the heme domain in this protein, with the
subsequent exposure of hydrophobic surface patches.
In crARC variants, the oligomeric state increases as the amino acid that is changed is closer to the
C-terminus (Figure 9b). A higher percentage oligomeric state occurs in E267A and R276A, which are
close to the C-termini. This could indicate that in crARC, the C-terminus may be involved in protein
aggregation to form the oligomers, because its alteration increases the oligomeric forms observed. Our
data also indicate that the degree of oligomerization is not related to the crARC reduction activity or to
the Mo Cofactor binding capacity.
In spite of the role that the mARC enzyme plays in prodrug activation, its exact biological function
remains elusive. mARC is able to reduce very different kinds of substrates, not all of them NHC, like
nitrite [18] and can use different kinds of partners, like NR [19]. ARCO is assumed to be involved
in the detoxification reactions of mutagenic and toxic NHCs like N-hydroxylated nucleobases and
nucleoside [9,10], as well as aromatic hydroxylamines [37].
In addition, in vitro studies have shown that human mARC is also able to catalyze the reduction
of the NO precursor NOHA to arginine [20]. A variety of several enzymes has been involved in NO
synthesis by reducing nitrite, and several of them are Mo enzymes [21]. It has been recently shown
that human mARC, apart from the NHC reductions, is also able to catalyse the reduction of nitrite to
NO using crCytb5-1 and crCytb5-R as partners under anaerobic conditions [18]. In Chlamydomonas,
we have described that the Mo enzyme NR is able to replace the function of crCytb5-R and crCytb5-1
and it can transfer the electrons from NAD(P)H to crARC, which synthesizes NO from nitrite [19].
It is also interesting to note, that various investigations identified linkages to energy metabolism [38],
notably diabetic mellitus [39] and lipid synthesis [31]. Interestingly the down-regulation of the human
mARC resulted in a significant decrease of the intracellular lipid levels [31]. However, the exact role of
mARC in these fields like lipid synthesis will require further research.
4. Materials and Methods
4.1. Chemicals
HAP was purchased from ICN Biochemicals (Irvine, CA, USA). The other chemicals were
purchased from Sigma-Aldrich (Madrid, Spain).
4.2. Bacterial Strains and Culture Conditions
The E. coli strains were grown on LB (Luria-Bertani) medium. The E. coli strain TP1000 (mobA) [40]
was used for the expression of crARC because it accumulates eukaryotic Mo Cofactor. The E. coli strain
BL21 (DE3) [41] was used for the expression of crCytb5-1 and crCytb5-R.
4.3. Cloning of cDNA for Recombinant Protein Expression.
The generation of the cysteine to alanine mutants of crARC was performed by PCR
mutagenesis [42]; the primers used are shown in Table S1 (Online Resource 1) and obtained cDNAs
were cloned in pQE80, which allows the expression of N-terminal six Histidines tagged fusion proteins
in E. coli (Qiagen, Hilden, Germany).
4.4. Expression and Purification of Recombinant Proteins
Standard expression of the crARC and crARC cysteine to alanine mutants was performed in
freshly transformed E. coli TP1000. Cells were grown aerobically in LB medium to an OD550 equal to 0.1
before induction. TP1000 cells were induced with 10 µM isopropyl-β-D-thiogalactopyranoside (IPTG)
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and additionally supplemented with 0.1 mM sodium molybdate to initiate recombinant expression.
BL21 cells were induced with 100 µM IPTG for expression. crCyb5-1 and crCytb5-R were purified as
described previously [17]. Cells expressing proteins with heme groups were supplemented with 1 mM
aminolevulinic acid to support heme synthesis. After induction, the cells were grown for 36 h at 22 ◦C.
Purification of recombinant proteins was performed by the Ni-nitrilotriacetic acid (Ni-NTA) matrix,
as recommended by the supplier (Qiagen), under native conditions at 4 ◦C, using minimal volumes
of washing buffers to reduce dissociation of bound Mo from the proteins. The protein fractions were
analyzed by SDS-polyacrylamide gel electrophoresis and only the pure fractions were taken and
immediately desalted on a PD10 gel filtration column previously equilibrated with 100 mM Tris-HCl,
pH 7.2. Protein concentration was determined by UV absorption measurements using the calculated
extinction coefficient [43] of the analyzed polypeptides.
4.5. DNA Sequencing and Sequence Analysis
The DNA sequencing and sequence analysis were performed as described previously [17].
4.6. HAP and Adenine Quantification
HAP and adenine were separated and quantified by HPLC as described previously [17].
4.7. Benzamidine and Benzamidoxime Quantification
Benzamidoxime and Benzamidine were separated and quantified by HPLC as described
previously [26]. The HPLC analysis was performed on an Agilent series 1200 from Agilent Technologies
(Santa Clara, CA, USA).
4.8. The Quantification of the crARC Reduction Activity
The HAP or Benzamidoxime reduction by crARC was determined as described previously [19]
with minor modifications. Incubations were carried out under aerobic conditions at 37 ◦C in a
shaking water bath. For the enzyme system reconstituted in vitro for the crARC NADH-dependent
activity, standard incubation mixtures in a volume of 150 µL contained 100 pmol crARC, 10 pmol
crCyt b5-R, 100 pmol crCytb5-1, 1.0 mM NADH and 0.5 mM HAP or 1 mM of benzamidoxime and
100 mM potassium phosphate buffer at pH 6.5. After pre-incubating for 3 min at 37 ◦C, the reaction
was started by adding NADH, then terminated after 15 min by adding 150 µL of methanol. For
the crARC dithionite-dependent activity, standard incubation mixtures of the reconstituted system
contained crARC 100 pmol, 0.5 mM HAP or 1 mM benzamidoxime, 2 mM benzylviologen and 3 mM
dithionite in 100 mM potassium phosphate buffer at pH 7.4. After 3 min of pre-incubation at 37 ◦C, the
reaction was started by adding dithionite and terminated after 15 min by adding 15% methanol. After
centrifugation, the supernatant was analyzed by HPLC. The protein mixture used for the SEC was
15 pmol crARC, 15 pmol crCyt b5-R, 15 pmol crCytb5-1, and the crARC reduction activity measure in
the same way as for the enzyme system reconstituted in vitro. One unit of crARC activity is defined as
the amount of enzyme causing the production of 1 µmol of adenine or benzamidine per minute under
the described conditions.
4.9. Determination of the Organic Motive of Mo Cofactor
To measure the amounts of Mo Cofactor bound to the proteins, its organic motif (MPT) was
analyzed by the Form A method, performed as reported [44].
4.10. Molecular Weight Determination by SEC
To determinate the Mw of native protein or the protein complex, the AKTA STAR chromatographic
system was used with the SEC column “Superdex 200 10/300 GL” from GE Healthcare (Barcelona,
Spain). The proteins amounts used for the SEC were 15 pmol for each one in the mixture. The
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chromatographic method was an isocratic phase with 50 mM of phosphate buffer at pH 7.2, 0.15 M of
NaCl and a flow rate of 0.75 mL/min. After the SEC, the fractions were collected and immediately
desalted on a PD10 gel filtration column previously equilibrated with 100 mM Tris-HCl, pH 7.2. Using
Mw markers proteins, a calibration curve was obtained representing the Mw versus the logarithm of
elution volume to obtain the Mw of any protein using its elution volume obtained after the SEC by
extrapolation. After the SEC, the protein amount was measure by the Bradford method [45].
4.11. Studies of Tertiary and Quaternary Structure of crARC Mutants
A fluorescence technique was used to determine whether the obtained crARC variants have the
same basic structure as the crARC wild protein. This technique measures the fluorescence emission
by the excitation of tyrosine, phenylalanine and tryptophan amino acids; tryptophans result in high
fluorescence emission [46]. With changing the environment of these amino acids, the fluorescence
emission varied. The crARC protein has 10 tryptophans in its 330 amino acids; therefore, it can be well
studied in environments with these 10 amino acids and if it has changed with respect to the wild type.
4.12. Software Used to Predict the Three-Dimensional Structure of crARC
The software used was the Swiss-PdbViewer Program of tertiary structures and three-dimensional
alignments of already crystallized structures online version, http://spdbv.vital-it.ch/Swiss-Model.
In the program, prediction of protein structures from their primary structure is based on searching
crystallized proteins with similar sequences, entropies and enthalpies; the most favorable and
crystallized protein-like structures are sought. The program outputs a .pdb file that we can view using
the Swiss-PdbViewer, http://swissmodel.expasy.org/AutoDockTools-1.5.6 was used to insert the Mo
Cofactor into crARC structure.
5. Conclusions
In conclusion, we have found that crARC activity is very stable over time. We have characterized
a protein complex formed between crARC and its partners crCytb5-1 and crCytb5-R. In addition,
the amino acids D182 and R276 are necessary in the NHC reduction activity, and F210 is essential
in Mo Cofactor binding. We have also found that the alteration in the crARC C-terminus causes an
oligomerization. Here, we have not addressed the crARC capacity to form NO from nitrite since it
depends on NR as the crARC partner. Future experiments will be designed to address the stoichiometry
and the role of the variants in the crARC-NR interaction for NO synthesis.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/3/670/s1.
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